|1.||Sun, Shi-Yong: 17 articles (12/2015 - 10/2004)|
|2.||Sakai, Toshiyuki: 15 articles (02/2014 - 08/2004)|
|3.||Khuri, Fadlo R: 14 articles (12/2015 - 10/2004)|
|4.||Liu, Xiangguo: 14 articles (11/2015 - 10/2004)|
|5.||Yue, Ping: 13 articles (12/2015 - 10/2004)|
|6.||Yagita, Hideo: 13 articles (11/2013 - 02/2004)|
|7.||Buchsbaum, Donald J: 12 articles (04/2011 - 04/2006)|
|8.||Horinaka, Mano: 11 articles (02/2014 - 08/2004)|
|9.||Yoshida, Tatsushi: 10 articles (01/2014 - 08/2004)|
|10.||Kim, Yong-Sung: 9 articles (06/2013 - 08/2007)|
05/15/2010 - "In this study, we have attempted to further improve the CTL induction and potent antitumor efficacy of a combination mAb-based therapy (termed "trimAb therapy") that comprises tumor cell death-inducing anti-death receptor 5 mAb and immune activating anti-CD40 and anti-CD137 mAbs. "
01/01/2014 - "In conclusion, targeting the UPS may represent a novel strategy to increase the cell surface expression of pro-apoptotic TRAIL-R on cancer cells and should be considered in clinical trials targeting TRAIL-receptors in cancer patients. "
01/01/2012 - "Failure to achieve therapeutic effects in recent clinical trials using TRAIL-receptors targeting compounds might be due to insufficient selection of patients bearing tumors with membrane-bound TRAIL-receptors."
09/01/2011 - "Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors."
09/01/2010 - "In this study, we report that death receptor 5 (DR5) is enriched in pancreatic CSCs compared with the bulk of the tumor cells. "
05/01/2007 - "Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model."
01/01/2015 - "The combination treatment further increases the sensitivity of carcinoma cells to apoptosis through FAS and TRAIL receptors but does not change the sensitivity of normal non-malignant epithelial cells. "
01/01/2014 - "Death receptor (DR4) haplotypes are associated with increased susceptibility of gallbladder carcinoma in north Indian population."
12/01/2010 - "The majority of primary pancreatic carcinoma samples and all cell lines express one or both agonistic TRAIL receptors. "
12/01/2010 - "TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors."
|3.||Colorectal Neoplasms (Colorectal Cancer)
01/01/2015 - "Mansoor et al reported that GG genotype in death receptor 4 played protective role however, CC genotype had a causative role in colorectal cancer in Pakistani population. "
12/01/2011 - "Coexpression of activated c-Met and death receptor 5 predicts better survival in colorectal carcinoma."
02/01/2008 - "DR5 receptor mediates anoikis in human colorectal carcinoma cell lines."
10/01/2006 - "Death receptor 4 variants and colorectal cancer risk."
11/27/1998 - "Genomic organization and mutation analyses of the DR5/TRAIL receptor 2 gene in colorectal carcinomas."
03/01/2009 - "High TRAIL death receptor 4 and decoy receptor 2 expression correlates with significant cell death in pancreatic ductal adenocarcinoma patients."
03/01/2006 - "Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma."
01/01/2013 - "Applying tissue microarray (TMA) analysis, we performed an immunohistochemical assessment of TRAIL-receptors in surgical samples from 84 consecutive patients affected by pancreatic adenocarcinoma and in 26 additional selected specimens from patients with no lymph nodes metastasis at the time of surgery. "
02/01/2012 - "The goal of the study was to assess the efficacy of combined extracellular matrix metalloprotease inducer (EMMPRIN)- and death receptor 5 (DR5)-targeted therapy for pancreatic adenocarcinoma in orthotopic mouse models with multimodal imaging. "
08/01/2009 - "peruviana were shown to have a significant reversal effect on TRAIL resistance in human gastric adenocarcinoma cells, and real-time PCR showed that thevefolin (2) enhanced mRNA expression of death receptor 4 (DR4) and DR5. "
05/01/2012 - "In this study, we evaluated the anti-tumor efficacy of humanized anti-death receptor 4 (DR4) antibody mapatumumab (Mapa) by comparing it with TRAIL in combination with hyperthermia. "
12/01/2012 - "In this study, we present a novel potent multimodality strategy comprising humanized death receptor 4 (DR4) antibody mapatumumab in combination with oxaliplatin and hyperthermia to treat human colon cancer cells. "
01/01/2013 - "Searching for the most clinically relevant approaches for treating colorectal metastatic disease by isolated hepatic perfusion (IHP), we developed the application of oxaliplatin concomitantly with hyperthermia and humanized death receptor 4 (DR4) antibody mapatumumab (Mapa), and investigated the molecular mechanisms of this multimodality treatment in human colon cancer cell lines CX-1 and HCT116 as well as human colon cancer stem cells Tu-12, Tu-21 and Tu-22. "
|4.||Immunoglobulin G (IgG)
|5.||Death Domain Receptors
|7.||Caspase 3 (Caspase-3)
|8.||CD147 Antigens (Basigin)
|10.||TNF-Related Apoptosis-Inducing Ligand
|1.||Drug Therapy (Chemotherapy)
|5.||Heterologous Transplantation (Xenotransplantation)